Vesey Street Taps Healthcare Titan Hilzinger for Strategic Edge

NEW YORK, NY – April 27, 2026 – In a move that underscores the increasing demand for deep operational expertise in private equity, Vesey Street Capital Partners (VSCP) has appointed Kurt Hilzinger, a distinguished figure in the healthcare industry, as Vice Chairman of its Strategic Advisory Board. The announcement signals a significant strategic enhancement for the healthcare-focused firm, positioning it to sharpen its competitive edge in the bustling lower middle-market.

While executive appointments are common, Hilzinger’s addition is being viewed by industry observers as a calculated masterstroke. It comes at a time when private equity investments in healthcare are hitting record highs, with global deal value exceeding $191 billion in 2025. In this crowded and complex landscape, firms like VSCP are finding that financial engineering alone is no longer sufficient; superior returns are increasingly driven by hands-on operational improvements and deep sector knowledge.

A Calculated Move for Operational Supremacy

Vesey Street Capital Partners has built its reputation on a disciplined, thesis-driven approach to the lower middle market—a segment where portfolio companies often require significant operational guidance to scale effectively. The firm’s strategy hinges on a hands-on partnership model, making the integration of seasoned industry veterans a cornerstone of its value-creation playbook.

"We are honored to welcome Kurt Hilzinger, a luminary in both the healthcare and private equity industries, to our firm," said Adam Feinstein, Founder & Managing Partner at VSCP. "I have known Kurt for over 30 years and believe that he brings a level of operational insight that aligns perfectly with our hands-on approach. As we grow, his deep expertise in building companies, M&A, and corporate strategy will be a vital resource for our management teams and partners."

This sentiment reflects a broader trend across private equity, where the role of the strategic advisor has evolved from a passive, relationship-based position to an active, integral part of the investment team. Firms are increasingly recruiting industry titans who can parachute into complex situations, diagnose operational inefficiencies, and guide management teams through intricate regulatory and market challenges. Hilzinger's appointment is a prime example of this modern approach to value creation.

A Legacy of High-Stakes Value Creation

Hilzinger’s career is a testament to his ability to navigate and lead through transformative periods in the healthcare sector. His track record is not one of incremental gains but of landmark achievements that have reshaped major industry players. His pivotal role in the formation of AmerisourceBergen (now Cencora) stands out as a defining accomplishment.

As President and COO, he was an architect of the landmark merger between AmeriSource Health Corp. and Bergen Brunswig Corp. More than just combining two entities, he led the complex integration of over 30 acquisitions, transforming the company’s business model to a more resilient fee-for-services approach. This experience in executing a large-scale buy-and-build strategy is directly applicable to VSCP's model of using add-on acquisitions to grow its platform companies.

Further burnishing his credentials is his long and impactful tenure at Humana Inc. Joining its board in 2003 and serving as Chairman since 2014, Hilzinger guided the health insurance giant through a period of immense growth and critical digital evolution. This provides him with an unparalleled perspective on the payor side of the healthcare ecosystem—a notoriously complex area where VSCP is actively investing. His experience is complemented by his time as a former partner and current executive advisor at Court Square Capital Partners, which gives him a deep, intrinsic understanding of the private equity lifecycle from deal sourcing to successful exit.

Targeting Healthcare's Most Complex Arenas

The strategic value of Hilzinger's appointment is magnified when considering VSCP's specific investment focus. The firm targets services that support hospitals, physician groups, life sciences companies, and payors. Hilzinger's expertise directly maps onto the two most intricate and opportunity-rich of these domains: the pharmaceutical supply chain and payor services.

"Kurt's addition strengthens our Strategic Advisory Board by expanding its depth of experience in both payor services and the pharmaceutical supply chain," noted Dave King, Chairman of VSCP's Strategic Advisory Board. "His perspective and operating experience will be very helpful across our portfolio companies."

This expertise is particularly timely. The global pharma supply-chain services market represents a massive profit pool, with outsourcing by pharmaceutical manufacturers driving sustained demand. Simultaneously, the payor services sector is projected to grow at a compound annual growth rate of over 24%, fueled by the relentless pressure to manage costs and improve efficiency. VSCP's portfolio, which includes companies in life sciences services and BPO/outsourced services, is well-positioned to benefit from Hilzinger’s insights into supply chain optimization, reimbursement models, and cost-containment strategies.

In his own words, Hilzinger acknowledged the unique opportunity at the firm. "VSCP has distinguished itself through a disciplined, thesis-driven approach to the lower middle market—a segment where operational expertise is the primary driver of outsized returns," he stated. "Having spent my career scaling healthcare platforms and navigating the intricacies of the supply chain, I look forward to partnering with the entire VSCP team to identify untapped opportunities and accelerate growth across the firm's dynamic portfolio."

Intensifying a Thesis in a Booming Market

Rather than signaling a pivot in strategy, Hilzinger’s appointment represents a deliberate intensification of VSCP’s established investment thesis. By embedding one of the industry's most respected operational leaders into its advisory core, the firm is doubling down on its belief that deep, sector-specific expertise is the ultimate differentiator.

This move strengthens VSCP’s ability to not only identify promising assets but also to actively accelerate their growth trajectories. With Hilzinger’s guidance on M&A integration, corporate strategy, and navigating regulatory bodies like the FDA and FTC, VSCP's portfolio companies gain a significant competitive advantage. For a firm that has already deployed over $1 billion of equity capital across 47 transactions, this enhancement of its operational capabilities is a clear signal of its ambition.

As the healthcare landscape continues to evolve, driven by technological innovation, regulatory shifts, and demographic pressures, the ability to combine capital with world-class operational acumen will define the most successful investors. By bringing Kurt Hilzinger into its inner circle, Vesey Street Capital Partners is making a definitive statement that it intends to be among that elite group, equipped to turn complexity into opportunity and build lasting value in the process.